Fampridine-PR (prolonged released 4-aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system.
J Peripher Nerv Syst
; 21(2): 85-7, 2016 06.
Article
en En
| MEDLINE
| ID: mdl-26968589
ABSTRACT
Fampridine-PR is a voltage-gated potassium channel inhibitor potentially improving nerve conduction in demyelinated axons. Based on its established clinical efficacy in patients with demyelination in the central nervous system, we assessed if fampridine-PR is also effective in patients with inflammatory demyelination of the peripheral nerve. In this small open-label study, 10 patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) were treated with fampridine-PR 10 mg BID for 28 days and assessed clinically as well as by nerve conduction studies. In this study, Fampridine-PR failed to improve CIDP based on clinical measures and nerve conduction studies. Our findings suggest that Fampridine-PR appears to be ineffective in demyelinating polyneuropathies. These observations may indicate a more complex mode of action beyond improving action potential conduction in demyelinated axons.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
4-Aminopiridina
/
Resultado del Tratamiento
/
Polirradiculoneuropatía Crónica Inflamatoria Desmielinizante
/
Bloqueadores de los Canales de Potasio
Límite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
J Peripher Nerv Syst
Asunto de la revista:
NEUROLOGIA
Año:
2016
Tipo del documento:
Article
País de afiliación:
Alemania